Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376263 | 0.87 | CHRNA7 (0.53) | CHRNA7HTR3ACHRM3CHRM2CHRM1 | |
| SCHEMBL5427615 | 0.87 | CHRNA7 (0.52) | CHRNA7CHRM3CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL5371766 | 0.86 | CHRNA7 (0.53) | CHRNA7HTR3ACHRM3CHRM2CHRM1 | |
| SCHEMBL5371799 | 0.85 | CHRNA7 (0.53) | CHRNA7HTR3ACHRM3CHRM2CHRM1 | |
| SCHEMBL5368280 | 0.85 | CHRNA7 (0.56) | CHRNA7HTR3A | |
| SCHEMBL5387562 | 0.84 | GRIN2B (0.37) | CHRNA7 | |
| SCHEMBL5954725 | 0.84 | CHRNA7 (0.35) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5374984 | 0.84 | CHRM3 (0.48) | CHRNA7HTR3ACHRM3CHRM2CHRM1 | |
| SCHEMBL5373638 | 0.82 | CHRM2 (0.49) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5367802 | 0.81 | CHRNA7 (0.42) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | PFIZER INC | 2006-06-01 | — | — | US | claimed |
| EP-1542999-A1 | 1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY | Pharmacia & Upjohn Company LLC (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PIOTROWSKI DAVID W (US) | 2004-05-06 | — | — | US | claimed |
| WO-2004013137-A1 | 1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-02-12 | — | — | WO | claimed |
| US-7176198-B2 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | PFIZER INC | 2006-06-01 | — | — | US | disclosed |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PIOTROWSKI DAVID W (US) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | CYP7B1, P2RX7, CYP3A7 | CHRNA7 8/4885CHRNB2 170/4885CHRNB4 217/4885 |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | CYP1B1, TPMT, CYP7B1 | CHRNA7 2586/4885CHRNB2 3958/4885CHRNB4 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.